Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > telcyta

Telcyta (TLK286) : Telik : small molecule compound

Telcyta (Telik)
Manufacturer's information on Telcyta, a targeted cancer therapy. Describes how Telcyta works against cancer and reviews clinical trials status.

Phase II Study of TLK286 (Telcyta) in combination with cisplatin as first-line treatment in locally advanced or metastatic NSCLC (ASCO)
Abstract of a phase II study of presented at the 2005 ASCO annual meeting designed to determine maximum tolerated dose (MTD) of Telcyta, its response rate and progression-free survival. Telcyta has been well-tolerated and active thus far, and trial is ongoing to establish final results. [5/05]

TELCYTA (TLK286) - Recent MEDLINE Abstracts (PubMed)

TELCYTA (TLK286) - Clinical Trials (ClinicalTrials.gov)


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor